

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

DHHS

Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.

## **Silver State Scripts Board Meeting Minutes**

**Date of Meeting**: Thursday, April 20, 2023, at 4:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record			Notes
1. Closed Executive Session				
a. Call to Order and Roll Call	Chairperson Mark Decerbo called the medon April 20, 2023.	eting to order a	it 4:05 p.m.	<ul> <li>DHCFP Staff Present were as follows:</li> <li>Lither, Gabriel, Senior Deputy Attorney General</li> </ul>
	Chairperson Decerbo took the roll.	<ul> <li>Clemons, Roshanda, MD,</li> <li>Medicaid Medical Director</li> <li>Olsen, David, Social Services</li> </ul>		
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$		Chief III
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$		Gudino, Antonio, Social Services
	Joseph Adashek, MD		$\boxtimes$	Program Specialist III (SSPS)
	Mark Crumby, Pharm. D.	$\boxtimes$		Berntson, Kindra, SSPS II
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$		<ul> <li>Flowers, Ellen, Program Officer I</li> </ul>
	Sapandeep Khurana, MD	$\boxtimes$		(PO)
	Isabella Niezborala, Pharm.D.	$\bowtie$		
	• Aditi Singh, MD			<ul> <li>Magellan Rx Staff Present were as follows:</li> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> <li>Martinez, Chris, Sr. Business Analyst</li> </ul>

b. Financial Review of Drug Classes with Proposed Changes	Chairman Decerbo directed Dr. Raj Mishra Financial Review of Drug classes with proper review.  Dr. Mishra reminded the board members the presented is confidential and should not be outside this closed session of the Silver State Dr. Mishra presented the Financial Review Classes with Proposed Changes, noting the changes in PDL status.  • Antipsychotics			
	MS, Oral			
2. Open Public Meeting				
a. Call to Order and Roll Call	Chairman Decerbo called the meeting to compare 20, 2023.  A quorum was present.  Chairman Decerbo took the roll.	order at 4:20 p.i	m. on April	<ul> <li>DHCFP Staff Present were as follows:</li> <li>Lither, Gabriel, Senior Deputy Attorney General</li> <li>Clemons, Roshanda, MD, Medicaid Medical Director</li> <li>Olsen, David, Social Services Chief III</li> </ul>
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm. D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> <li>Aditi Singh, MD</li> </ul>	Present    Control   Contr	Absent	<ul> <li>Gudino, Antonio, SSPS III</li> <li>Berntson, Kindra, SSPS II, Pharmacy Unit</li> <li>Ellen Flowers, PO I</li> <li>Magellan Rx Staff Present were as follows:         <ul> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> </ul> </li> </ul>

				<ul> <li>Martinez, Chris, Sr. Business         Analyst</li> <li>Chow, Connie, Pharm.D., Clinical         Account Manager</li> <li>The public attendee list is included as         Attachment A.         Note: Participants may not have chosen         to reveal their identity, and in the         absence of a sign-in sheet, the attendee         list's accuracy is not assured</li> </ul>
	b. Pu	ublic Comments	Telephonic and web comment was called for, and the phone lines were opened.  No public comments were provided.	
	c C+	tatus Update by	No announcements were provided.	
		HCFP	No announcements were provided.	
2		al Presentations		
Э.		or Possible Action:		
		iscussion and possible		
		doption of		
		ntipsychotics.		
	i.	Public comment	Telephonic and web comment was called for, and the phone lines were opened.	
			Public comment was provided by Kenneth Berry.	
	ii.	Drug class review	Dr. Mishra recommended the Board consider the class clinically and	
		presentation by	therapeutically equivalent.	
		MagellanRx		
	iii.	Discussion by	Chairman Decerbo moved to accept the class as clinically and	
		Board and action	therapeutically equivalent presented by Magellan, and Board	
L		by Board to	Member Sapandeep Khurana seconded the motion.	

	approve clinical/therapeutic equivalency of agents in class.	A vote was taken, and the results were as attendance (in favor, against, and abstent					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$				
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		<ul> <li>Mark Crumby, Pharm.D.</li> </ul>	$\boxtimes$				
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
		Sapandeep Khurana, MD	$\boxtimes$				
		<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>	$\boxtimes$				
		Aditi Singh, MD			$\boxtimes$		
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended moving brand I preferred and adding their generic lurasid the PDL as preferred.	_				
V.	Discussion by Board and action by Board for approval of drugs for inclusion	Vice-Chair Kate Ward moved to approve to presented by Magellan and Board Member motion.			_		
	on the PDL.	A vote was taken, and the results were as attendance (in favor, against, and abstent					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$				
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		Mark Crumby, Pharm.D.	$\boxtimes$				
		Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
		Sapandeep Khurana, MD	$\boxtimes$				
		Isabella Niezborala, Pharm.D.	$\boxtimes$				
		Aditi Singh, MD			$\boxtimes$		

Discussion and possible					
adoption of MS, Oral.					
i. <u>Public comment</u>	Telephonic and web comment was called were opened.				
	No public comment was provided.				
ii. Drug class review	Dr. Mishra recommended the Board cons	ider the cla	ass clin	ically and	
presentation by MagellanRx	therapeutically equivalent.				
iii. Discussion by Board and action by Board to approve	Chairman Decerbo moved to accept the of the rapeutically equivalent presented by Mard seconded the motion.				
clinical/therapeu tic equivalency of agents in	A vote was taken, and the results were as attendance (in favor, against, and absten				
class.		Yes	No	Abst.	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$			
	<ul> <li>Kate Ward, Pharm.D., Vice-Chair</li> </ul>	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	Mark Crumby, Pharm.D.	$\boxtimes$			
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D.	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
		Aubagio an	-L C:L-		

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to approve the presented by Magellan and Board Membership.  A vote was taken, and the results were as attendance (in favor, against, and abster				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	Mark Crumby, Pharm.D.	$\boxtimes$			
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
C. Closing Discussion					
<ul> <li>i. Public comments on any subject</li> </ul>	No public comments were provided.				
ii. Date and location	Date: June 22, 2023.	•			
of the next meeting.	Location: TBD				
iii. Adjournment	Chairman Decerbo adjourned the meetir	ng at 4:42 P	M.		

## Attachment A – Members of the Public in Attendance

Pulver, Lisa [JANUS] Hale, Amy [JANUS]

Shelly Nickerson Joe Gelinas Kenneth Berry Michael Zarob

## Attachment B – Submitted Written Comment

None